Assessment of the impact of different SARS-CoV-2 inactivation operations on colistin sulfate plasma concentration results.

Assessment of the impact of different SARS-CoV-2 inactivation operations on colistin sulfate plasma concentration results.

Publication date: Jan 03, 2025

To evaluate the effects of different SARS-CoV-2 inactivation methods on the blood concentration of colistin sulfate. A colistin sulfate reference substance, a quality control plasma sample, and a clinically measured sample were transferred and heated in a 56 ^0C water batch for 30 min or irradiated under an ultraviolet (UV) lamp for 60 min to examine the stability of the reference solution and quality control plasma sample. Statistical analysis was conducted for the concentration of the clinically measured sample before and after inactivation with the intraclass correlation coefficient (ICC) method, the Passing-Bablok regression, and the Bland-Altman analysis. The reference substance of colistin sulfate was unstable under UV inactivation. Under moist heat inactivation, the reference substance and quality control plasma sample of colistin sulfate were stable. The ICC of the concentration results of 27 clinical blood samples with and without moist heat inactivation was 0. 995 (P 

Open Access PDF

Concepts Keywords
30min Colistin sulfate
Bland Plasma concentration
Blood SARS-CoV-2
Colistin Therapeutic drug monitoring
Plasma Virus inactivation

Semantics

Type Source Name
drug DRUGBANK Colistin
drug DRUGBANK Sulfate ion
disease IDO blood
disease IDO quality
drug DRUGBANK Water
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH virus infection
drug DRUGBANK Etoperidone
disease MESH COVID 19
disease MESH Emergency
disease MESH fungal infections
disease MESH bacterial infections
disease MESH infections
disease IDO bacteria
disease IDO infection
drug DRUGBANK Dimercaprol
drug DRUGBANK Formic Acid
drug DRUGBANK Flunarizine
drug DRUGBANK Ademetionine
drug DRUGBANK Vildagliptin
drug DRUGBANK Cysteamine
disease MESH Middle East respiratory syndrome
drug DRUGBANK Ethanol
drug DRUGBANK Chlorine
drug DRUGBANK Peracetic acid
pathway KEGG Viral replication
disease MESH hemolysis
disease IDO process
drug DRUGBANK Trestolone
disease MESH clinical significance
drug DRUGBANK L-Valine
disease IDO deoxyribonucleic acid
disease IDO ribonucleic acid
disease MESH Return to work
drug DRUGBANK Colistimethate
disease MESH critically ill
disease MESH pneumonia

Original Article

(Visited 1 times, 1 visits today)